Search
3-Methylfentanyl
go.drugbank.com/drugs/DB01571ExperimentalIllicit3-Methylfentanyl is an opioid analgesic and is an analog of the potent opioid, fentanyl. 3-Methylfentanyl is one of the most powerful opioid drugs sold illegally and is estimated to be between 400-6000 times more potent than morphine in ...
Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigationalSibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker. APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells. Elevated APRIL levels are often observed in inflammatory disord...
Ephedra sinica root
go.drugbank.com/drugs/DB01363ApprovedNutraceuticalEphedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements intended to increase muscle weight or promote weight loss was banned in the United States in 2004 d...
TST10088
go.drugbank.com/drugs/DB05151ExperimentalThese molecules efficiently kill cells by activating preprogrammed death pathways known as apoptosis.
PX-12
go.drugbank.com/drugs/DB05448InvestigationalSince high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced
humanized SMART Anti-IL-12 Antibody
go.drugbank.com/drugs/DB05848ExperimentalIL-12 is a cytokine that may have considerable potential as a target in the therapy of autoimmune diseases.
RUTI® Vaccine
go.drugbank.com/drugs/DB15853InvestigationalMuch like the BCG vaccine, the RUTI® vaccine is also being tested as a prophylactic for SARS-CoV2.
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAffitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.